From USFDA
Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg (ANDA 202223). The product is ready for launch.Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg are the generic equivalent to the reference listed drug product (RLD) Diovan Tablets, 40mg, 80mg, 160mg and 320mg respectively of Novartis Pharmaceuticals Corporation (Novartis) and indicated for the treatment of hypertension, to lower blood pressure. The product falls under the therapeutic category of CVS (Cardio Vascular) has a market size of approximately US$ 2 Billion for the twelve months ending October 2014 according to IMS.
Powered by Capital Market - Live News
